Rheumatology 2002; 41: 1052-1061
© 2002 British Society for Rheumatology
Original papers |
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis
Clinical Pharmacology, Merck Research Laboratories, Rahway, NJ,
1 Department of Medicine, Northwestern University Medical School, Chicago, IL,
2 Health Research of Hampton Roads, Newport News, VA,
3 Arthritis Northwest, Seattle, WA,
4 Hospital for Special Surgery, New York, NY,
5 Clinical Biostatistics, Merck Research Laboratories, Rahway, NJ and
6 Pulmonary-Immunology, Merck Research Laboratories, Rahway, NJ, USA
Objectives. To evaluate the clinical efficacy and tolerability of etoricoxib in the treatment of osteoarthritis (OA) of the knee and define the clinically active dose range for further clinical trials.
Methods. This two-part, randomized, double-blind, placebo- and active comparator-controlled trial was conducted in 617 adults with knee OA. In Part 1 (6 weeks), patients received placebo, etoricoxib 5, 10, 30, 60 or 90 mg q.d. In Part 2 (8 weeks), patients received etoricoxib 30, 60 or 90 mg q.d. or diclofenac 50 mg t.i.d., predetermined at Part 1 allocation. Efficacy and safety were evaluated. Primary efficacy end-points were the Western Ontario and McMaster's University Osteoarthritis Index (WOMAC) Pain subscale, Patient Global Assessment of Response to Therapy, and Investigator Global Assessment of Disease Status.
Results. At 6 weeks, etoricoxib 5, 10, 30, 60 and 90 mg each demonstrated clinical efficacy superior to placebo. Maximal efficacy was seen with 60 mg. In Part 2, etoricoxib 30, 60 and 90 mg were generally similar to diclofenac. Patients receiving etoricoxib 30, 60 or 90 mg in Parts I and II had sustained effects over 14 weeks. All treatments were well tolerated.
Conclusions. Etoricoxib 60 mg once daily showed maximal efficacy in treating OA in this study. Etoricoxib 5–90 mg once daily was generally well tolerated in OA patients for up to 14 weeks.
KEY WORDS: Etoricoxib, Osteoarthritis, Efficacy, Safety, Tolerability.
Correspondence to: L. DeTora, Merck & Co, 126 E. Lincoln Ave., RY 32-305, Rahway, NJ 07065, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Chilet-Rosell, M. T. Ruiz-Cantero, and J. F. Horga Women's health and gender-based clinical trials on etoricoxib: methodological gender bias J. Public Health Med., September 1, 2009; 31(3): 434 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Schwartz, N. G. B. Agrawal, U. A. Kher, M. DeSmet, P. F. Cavanaugh Jr, M. Guillaume, D. L. Ebel, S. A. Merschman, and J. A. Wagner Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib J. Clin. Pharmacol., October 1, 2007; 47(10): 1342 - 1346. [Full Text] [PDF]
|
|
|
|
 |
|
 P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Schwartz, N. G. B. Agrawal, A. H. Hartford, J. Cote, T. L. Hunt, R. Verbesselt, D. R. Eckols, and K. M. Gottesdiener The Effect of Etoricoxib on the Pharmacodynamics and Pharmacokinetics of Warfarin J. Clin. Pharmacol., May 1, 2007; 47(5): 620 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Bingham III, A. I. Sebba, B. R. Rubin, G. E. Ruoff, J. Kremer, S. Bird, S. S. Smugar, B. J. Fitzgerald, K. O'Brien, and A. M. Tershakovec Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies Rheumatology, March 1, 2007; 46(3): 496 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tsoukas, M. E. Eyster, S. Shingo, S. Mukhopadhyay, K. M. Giallella, S. P. Curtis, A. S. Reicin, and A. Melian Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy Blood, March 1, 2006; 107(5): 1785 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D Martina, K. S Vesta, and T. L Ripley Etoricoxib: A Highly Selective COX-2 Inhibitor Ann. Pharmacother., May 1, 2005; 39(5): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. B. Agrawal, C. Z. Matthews, R. S. Mazenko, E. J. Woolf, A. G. Porras, X. Chen, J. L. Miller, N. Michiels, M. Wehling, A. Schultz, et al. The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity J. Clin. Pharmacol., October 1, 2004; 44(10): 1125 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. B. Agrawal, C. Z. Matthews, R. S. Mazenko, W. F. Kline, E. J. Woolf, A. G. Porras, L. A. Geer, P. H. Wong, M. Cho, J. Cote, et al. Pharmacokinetics of Etoricoxib in Patients with Renal Impairment J. Clin. Pharmacol., January 1, 2004; 44(1): 48 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. B. Agrawal, M. J. Rose, C. Z. Matthews, E. J. Woolf, A. G. Porras, L. A. Geer, P. J. Larson, J. Cote, S. C. Dilzer, K. C. Lasseter, et al. Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment J. Clin. Pharmacol., October 1, 2003; 43(10): 1136 - 1148. [Abstract] [Full Text] [PDF]
|
|